Pfizer Inc. (NYSE:PFE) Shares Sold by Hutchinson Capital Management CA

Hutchinson Capital Management CA reduced its position in Pfizer Inc. (NYSE:PFE) by 14.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,246 shares of the biopharmaceutical company’s stock after selling 4,766 shares during the period. Hutchinson Capital Management CA’s holdings in Pfizer were worth $723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. one8zero8 LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $1,656,000. Van Strum & Towne Inc. lifted its stake in shares of Pfizer by 5.5% in the 4th quarter. Van Strum & Towne Inc. now owns 69,684 shares of the biopharmaceutical company’s stock valued at $1,849,000 after purchasing an additional 3,655 shares during the period. Brandes Investment Partners LP lifted its stake in shares of Pfizer by 16.8% in the 4th quarter. Brandes Investment Partners LP now owns 6,708,164 shares of the biopharmaceutical company’s stock valued at $177,968,000 after purchasing an additional 962,837 shares during the period. Zevin Asset Management LLC lifted its stake in shares of Pfizer by 46.0% in the 4th quarter. Zevin Asset Management LLC now owns 16,182 shares of the biopharmaceutical company’s stock valued at $429,000 after purchasing an additional 5,095 shares during the period. Finally, Hills Bank & Trust Co lifted its stake in shares of Pfizer by 1.9% in the 4th quarter. Hills Bank & Trust Co now owns 71,214 shares of the biopharmaceutical company’s stock valued at $1,889,000 after purchasing an additional 1,339 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.5 %

Shares of PFE stock opened at $25.74 on Friday. The company’s 50-day moving average price is $26.24 and its 200-day moving average price is $27.13. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $145.85 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PFE shares. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.